On December 8, the 8th "Maker China" Beijing SME Innovation and Entrepreneurship Competition—also known as "Maker Beijing 2023"—concluded successfully. Beijing tricision Biotech Co., Ltd. (tricision) was awarded the Special Award in the "Xiuzheng · Pharmaceutical and Health Industry Special Competition", and its project was selected for inclusion in the Beijing High-Precision Industry Project Reserve Pool, qualifying it for priority support from central and municipal government funding.

The "Maker China" Beijing SME Innovation and Entrepreneurship Competition is guided by the Ministry of Industry and Information Technology and the Ministry of Finance, and co-hosted by the Beijing Municipal Bureau of Economy and Information Technology, the Beijing Municipal Finance Bureau, and the Fangshan District People's Government. Over the course of the three-month competition, 5,053 projects were showcased. tricision distinguished itself through multiple rounds of evaluation with its project "Pan-Solid Tumor mRNA-Dendritic Cell (mRNA-DC) Precision Therapeutic Vaccine Platform Based on Shared Antigens," emerging from a highly competitive field of outstanding projects.

As one of China's earliest biopharmaceutical companies to achieve breakthroughs in mRNA-based cancer vaccine development and immunotherapy, tricision has built a complete industrial chain spanning core technology R&D, product design, raw material production, and market deployment. The Company holds significant advantages in technology, production capacity, and clinical application.

tricision's lead candidate—the Survivin-Targeting DC Cell Injection for primary Glioblastoma Multiforme (GBM)—received Clinical Trial Permission (CTP) from the Center for Drug Evaluation (CDE) on January 10, 2023, making it China's first mRNA-DC therapeutic cancer vaccine to receive clinical trial approval. This recognition at "Maker Beijing 2023" further validates tricision's pioneering role in the mRNA-DC field and its potential to reshape the treatment landscape for solid tumors.